ReviewWorld journal of gastroenterology2014
Current and future molecular diagnostics in colorectal cancer and colorectal adenoma.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis.International journal of clinical pharmacy · 2019Pooled it
- Screening and treatment of psychological distress in patients with metastatic colorectal cancer: study protocol of the TES trial.BMC cancer · 2015Trial
- Understanding Cancer Health Disparities.Cancers · 2026Review
- Predictive role of [EJNMMI reports · 2024Article
- Review
- Is Insulin Receptor Substrate4 (IRS4) a Platform Involved in the Activation of Several Oncogenes?Cancers · 2023Review
- Serrated Colorectal Lesions: An Up-to-Date Review from Histological Pattern to Molecular Pathogenesis.International journal of molecular sciences · 2022Review
- Comparison of Next-Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment-Related Genomic Status in Patients with Metastatic Colorectal Cancer.Current issues in molecular biology · 2022Article
- Automatic Colorectal Cancer Screening Using Deep Learning in Spatial Light Interference Microscopy Data.Cells · 2022Article
- The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis.Pathology oncology research : POR · 2022Review
- Combination of GC-MS based metabolomics analysis with mouse xenograft models reveals a panel of dysregulated circulating metabolites and potential therapeutic targets for colorectal cancer.Translational cancer research · 2021Article
- Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements.International journal of molecular sciences · 2020Review
- A Focused Review on Advances in Risk Stratification of Malignant Polyps.Gastroenterology research · 2020Review
- Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?Cancers · 2020Review
- Genetically Engineered Pigs to Study Cancer.International journal of molecular sciences · 2020Review
- Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC).Diagnostics (Basel, Switzerland) · 2019Review
- Positive expression of basic transcription factor 3 predicts poor survival of colorectal cancer patients: possible mechanisms involved.Cell death & disease · 2019Article
- The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy.Oncology letters · 2018Review
- Miniaturized Real-Time PCR on a Q3 System for Rapid KRAS Genotyping.Sensors (Basel, Switzerland) · 2017Article
- Expression of PI3Kp110α and PI3Kp110β in the colorectal conventional adenoma, serrated lesions and adenoma with canceration and their significance.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the most prevalent cancers in developed countries. On the other hand, CRC is also one of the most curable cancers if it is detected in early stages through regular colonoscopy or sigmoidoscopy. Since CRC develops slowly from precancerous lesions, early detection can reduce both the incidence and mortality of the disease. Fecal occult blood test is a widely used non-invasive screening tool for CRC. Although fecal occult blood test is simple and cost-effective in screening CRC, there is room for improvement in terms of the accuracy of the test. Genetic dysregulations have been found to play an important role in CRC development. With better understanding of the molecular basis of CRC, there is a growing expectation on the development of diagnostic tests based on more sensitive and specific molecular markers and those tests may provide a breakthrough to the limitations of current screening tests for CRC. In this review, the molecular basis of CRC development, the characteristics and applications of different non-invasive molecular biomarkers, as well as the technologies available for the detection were discussed. This review intended to provide a summary on the current and future molecular diagnostics in CRC and its pre-malignant state, colorectal adenoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.